NewcelX（NCEL）株式概要バイオ医薬品会社であるニューセルX社は、糖尿病に対する革新的な幹細胞由来の治療法の開発に取り組んでいる。 詳細NCEL ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去5年間で収益は年間9.7%減少しました。 US市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( $0 )意味のある時価総額がありません ( $18M )すべてのリスクチェックを見るNCEL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$3.49該当なし内在価値ディスカウントEst. Revenue$PastFuture-8m442k2016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesNewcelX Ltd. 競合他社Passage BioSymbol: NasdaqCM:PASGMarket cap: US$18.2mCEL-SCISymbol: NYSEAM:CVMMarket cap: US$18.2mTempest TherapeuticsSymbol: NasdaqCM:TPSTMarket cap: US$18.2mAtossa TherapeuticsSymbol: NasdaqCM:ATOSMarket cap: US$17.3m価格と性能株価の高値、安値、推移の概要NewcelX過去の株価現在の株価US$3.4952週高値US$7.6452週安値US$1.83ベータ01ヶ月の変化10.44%3ヶ月変化44.21%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-52.13%最新ニュースお知らせ • Jun 15NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology PlatformNewcelX announced the publication of a peer-reviewed study in Stem Cell Reports, investigating the potential of AstroRx, a clinical-grade human embryonic stem cells (hESC)-derived astrocyte therapy, which recently completed a successful Phase 1/2a clinical trial in amyotrophic lateral sclerosis (ALS), as a novel and translationally relevant cell therapy for multiple sclerosis (MS), and other chronic demyelinating diseases. The publication further validates NewcelX’s ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications. The study, titled “Pro-repair properties of a human embryonic stem cell–derived astrocyte cell therapy in experimental multiple sclerosis,” was developed in collaboration with researchers at several highly regarded institutions, including the Hebrew University of Jerusalem Hadassah Medical School. Data demonstrated that AstroRx addresses key barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes. These effects were observed both in-vitro and in an in-vivo lysolecithin-induced demyelination model. Key findings from the study include the potential for AstroRx® to: enhance myelin debris clearance by microglia, support lymphocyte-mediated immune regulation, and accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes.お知らせ • Jun 09NewcelX Ltd., Annual General Meeting, Jun 30, 2026NewcelX Ltd., Annual General Meeting, Jun 30, 2026, at 14:00 W. Europe Standard Time. Location: baker mckenzie switzerland ag, holbeinstrasse 30, 8034 switzerland, zurich Switzerlandお知らせ • May 01NewcelX Ltd. announced that it has received $1.349994 million in fundingOn April 30, 2026, NewcelX Ltd. closed the transaction.お知らせ • Apr 02NewcelX Ltd. announced that it expects to receive $1.349994 million in fundingNewcelX Ltd. announced that it has entered into a securities purchase agreement to issue 490,907 common shares or pre-funded warrants at an issue price of $2.75 per share for gross proceeds of $1,349,994.25 and one series of warrants to purchase 687,270 common shares at an exercise price of $3.025 per share for aggregate proceeds of $1,349,994.25 on April 1, 2026. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions. The securities are being issued in a private placement under section 4(a)(2) of the securities act of 1933, as amended), and Regulation D promulgated thereunder and have not been registered under the securities act, or applicable state securities laws.New Risk • Mar 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.57m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Mar 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (US$11.9m market cap).最新情報をもっと見るRecent updatesお知らせ • Jun 15NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology PlatformNewcelX announced the publication of a peer-reviewed study in Stem Cell Reports, investigating the potential of AstroRx, a clinical-grade human embryonic stem cells (hESC)-derived astrocyte therapy, which recently completed a successful Phase 1/2a clinical trial in amyotrophic lateral sclerosis (ALS), as a novel and translationally relevant cell therapy for multiple sclerosis (MS), and other chronic demyelinating diseases. The publication further validates NewcelX’s ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications. The study, titled “Pro-repair properties of a human embryonic stem cell–derived astrocyte cell therapy in experimental multiple sclerosis,” was developed in collaboration with researchers at several highly regarded institutions, including the Hebrew University of Jerusalem Hadassah Medical School. Data demonstrated that AstroRx addresses key barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes. These effects were observed both in-vitro and in an in-vivo lysolecithin-induced demyelination model. Key findings from the study include the potential for AstroRx® to: enhance myelin debris clearance by microglia, support lymphocyte-mediated immune regulation, and accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes.お知らせ • Jun 09NewcelX Ltd., Annual General Meeting, Jun 30, 2026NewcelX Ltd., Annual General Meeting, Jun 30, 2026, at 14:00 W. Europe Standard Time. Location: baker mckenzie switzerland ag, holbeinstrasse 30, 8034 switzerland, zurich Switzerlandお知らせ • May 01NewcelX Ltd. announced that it has received $1.349994 million in fundingOn April 30, 2026, NewcelX Ltd. closed the transaction.お知らせ • Apr 02NewcelX Ltd. announced that it expects to receive $1.349994 million in fundingNewcelX Ltd. announced that it has entered into a securities purchase agreement to issue 490,907 common shares or pre-funded warrants at an issue price of $2.75 per share for gross proceeds of $1,349,994.25 and one series of warrants to purchase 687,270 common shares at an exercise price of $3.025 per share for aggregate proceeds of $1,349,994.25 on April 1, 2026. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions. The securities are being issued in a private placement under section 4(a)(2) of the securities act of 1933, as amended), and Regulation D promulgated thereunder and have not been registered under the securities act, or applicable state securities laws.New Risk • Mar 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.57m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Mar 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (US$11.9m market cap).お知らせ • Jan 13Newcelx Ltd. Announces Positive Results from International Collaborative StudyNewcelX Ltd. reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell-derived islets for the treatment of Type 1 Diabetes. The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin-Madison, Monash University, the Queensland University of Technology, and the Australian Foundation for Diabetes Research (AFDR), examined the use of engineered scaffolds incorporating extracellular matrix (ECM) derived from a decellularized human pancreas. The work evaluated whether ECM integration could support the function of encapsulated pluripotent stem cell-derived islets within a removable delivery system. The study results demonstrated that when ECM was incorporated into the scaffold, implanted islets exhibited functional performance comparable to encapsulated islets delivered without a scaffold. These findings suggest that biomaterial design and tissue microenvironment play a critical role in supporting islet function and may enable safer, retrievable delivery configurations for future therapeutic development. The research was supported through a Type 1 Diabetes research initiative led by the Australian Foundation for Diabetes Research, which had received donor matched funding for the published study from the National Stem Cell Foundation of Australia. Moreover, it has received dedicated funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, to further develop the underlying model based on the study results. The program integrates proprietary cell differentiation protocols with immune-protective and delivery-oriented design features, with the goal of achieving functional insulin secretion without the need for systemic immunosuppression.お知らせ • Jan 05NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory BoardNewcelX Ltd. announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership, to its Scientific Advisory Board. Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes. In joining the NewcelX Scientific Advisory Board, Dr. Boisdron will provide high-level strategic guidance supporting the development of IsletRx, NewcelX's lead therapeutic program, a stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. Dr. Boisdron will advise on translational strategy as NewcelX advances the program toward clinical trials, including patient-adoption considerations, health-system integration, and future global commercialization frameworks.New Risk • Dec 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.75m market cap).お知らせ • Nov 18NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory BoardNewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board. Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and research of neurological diseases that is home to one of the largest multidisciplinary brain and spine programs in the United States and the world's largest Phase 0 clinical trials program advancing innovative neurotherapeutics Link. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS) and has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures Link. In his role on the SAB of NewcelX, Prof. Shefner will provide strategic guidance on the Company's programs in ALS, including the clinical development of AstroRx, and will support the integration of neuromuscular and neurodegenerative disease expertise into the Company's broader platform of cell therapy and neuroscience innovation.お知らせ • Nov 07NewcelX Ltd. Appoints Tamir Ben-Hur as Scientific Advisory BoardNewcelX Ltd. announced that Professor Tamir Ben-Hur, MD, PhD, a renowned neurologist and long-time scientific advisor of Kadimastem Ltd., will join the Company's Scientific Advisory Board. Prof. Ben-Hur, a Professor of Neurology at Hadassah University Medical Center and the Hebrew University of Jerusalem, is widely recognized as a global expert in neuroimmunology and stem-cell-based regenerative medicine. The commitment of Prof. Ben-Hur to join the NewcelX Scientific Advisory Board represents a strong endorsement of the Merger and the scientific foundation on which NewcelX is being built — uniting Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). Independent External Director Liora Oren was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.株主還元NCELUS BiotechsUS 市場7D9.1%2.8%-1.8%1Yn/a35.2%23.3%株主還元を見る業界別リターン: NCELがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: NCEL US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is NCEL's price volatile compared to industry and market?NCEL volatilityNCEL Average Weekly Movement19.8%Biotechs Industry Average Movement10.7%Market Average Movement7.3%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: NCELの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: NCELの weekly volatility ( 20% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200811Ronen Twitonewcelx.comバイオ医薬品会社であるNewcelX Ltd.は、糖尿病のための革新的な幹細胞由来治療法の開発に取り組んでいる。同社は、1型糖尿病および2型インスリン依存性糖尿病の治療薬として、濃縮膵島様クラスターに基づく細胞治療製品NCEL-101、筋萎縮性側索硬化症および神経変性適応症の治療薬として、既製の凍結保存細胞治療製品AstroRxを開発している；および睡眠障害、神経変性／神経炎症性疾患、糖尿病関連神経疾患の治療を目的とした低分子プラットフォームであるデュアル・オレキシン受容体アゴニスト（DOXA）を開発している。また、iTOL-102、NCEL-201、NCEL-301、NCEL-007も開発している。NewcelX Ltd.は2008年に設立され、スイスのクローテンに本社を置いている。もっと見るNewcelX Ltd. 基礎のまとめNewcelX の収益と売上を時価総額と比較するとどうか。NCEL 基礎統計学時価総額US$17.82m収益（TTM）-US$8.30m売上高(TTM)n/a0.0xP/Sレシオ-2.3xPER（株価収益率NCEL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NCEL 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$8.30m収益-US$8.30m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-1.54グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率4.9%NCEL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/22 17:42終値2026/06/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NewcelX Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 15NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology PlatformNewcelX announced the publication of a peer-reviewed study in Stem Cell Reports, investigating the potential of AstroRx, a clinical-grade human embryonic stem cells (hESC)-derived astrocyte therapy, which recently completed a successful Phase 1/2a clinical trial in amyotrophic lateral sclerosis (ALS), as a novel and translationally relevant cell therapy for multiple sclerosis (MS), and other chronic demyelinating diseases. The publication further validates NewcelX’s ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications. The study, titled “Pro-repair properties of a human embryonic stem cell–derived astrocyte cell therapy in experimental multiple sclerosis,” was developed in collaboration with researchers at several highly regarded institutions, including the Hebrew University of Jerusalem Hadassah Medical School. Data demonstrated that AstroRx addresses key barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes. These effects were observed both in-vitro and in an in-vivo lysolecithin-induced demyelination model. Key findings from the study include the potential for AstroRx® to: enhance myelin debris clearance by microglia, support lymphocyte-mediated immune regulation, and accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes.
お知らせ • Jun 09NewcelX Ltd., Annual General Meeting, Jun 30, 2026NewcelX Ltd., Annual General Meeting, Jun 30, 2026, at 14:00 W. Europe Standard Time. Location: baker mckenzie switzerland ag, holbeinstrasse 30, 8034 switzerland, zurich Switzerland
お知らせ • May 01NewcelX Ltd. announced that it has received $1.349994 million in fundingOn April 30, 2026, NewcelX Ltd. closed the transaction.
お知らせ • Apr 02NewcelX Ltd. announced that it expects to receive $1.349994 million in fundingNewcelX Ltd. announced that it has entered into a securities purchase agreement to issue 490,907 common shares or pre-funded warrants at an issue price of $2.75 per share for gross proceeds of $1,349,994.25 and one series of warrants to purchase 687,270 common shares at an exercise price of $3.025 per share for aggregate proceeds of $1,349,994.25 on April 1, 2026. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions. The securities are being issued in a private placement under section 4(a)(2) of the securities act of 1933, as amended), and Regulation D promulgated thereunder and have not been registered under the securities act, or applicable state securities laws.
New Risk • Mar 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.57m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Mar 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (US$11.9m market cap).
お知らせ • Jun 15NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology PlatformNewcelX announced the publication of a peer-reviewed study in Stem Cell Reports, investigating the potential of AstroRx, a clinical-grade human embryonic stem cells (hESC)-derived astrocyte therapy, which recently completed a successful Phase 1/2a clinical trial in amyotrophic lateral sclerosis (ALS), as a novel and translationally relevant cell therapy for multiple sclerosis (MS), and other chronic demyelinating diseases. The publication further validates NewcelX’s ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications. The study, titled “Pro-repair properties of a human embryonic stem cell–derived astrocyte cell therapy in experimental multiple sclerosis,” was developed in collaboration with researchers at several highly regarded institutions, including the Hebrew University of Jerusalem Hadassah Medical School. Data demonstrated that AstroRx addresses key barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes. These effects were observed both in-vitro and in an in-vivo lysolecithin-induced demyelination model. Key findings from the study include the potential for AstroRx® to: enhance myelin debris clearance by microglia, support lymphocyte-mediated immune regulation, and accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes.
お知らせ • Jun 09NewcelX Ltd., Annual General Meeting, Jun 30, 2026NewcelX Ltd., Annual General Meeting, Jun 30, 2026, at 14:00 W. Europe Standard Time. Location: baker mckenzie switzerland ag, holbeinstrasse 30, 8034 switzerland, zurich Switzerland
お知らせ • May 01NewcelX Ltd. announced that it has received $1.349994 million in fundingOn April 30, 2026, NewcelX Ltd. closed the transaction.
お知らせ • Apr 02NewcelX Ltd. announced that it expects to receive $1.349994 million in fundingNewcelX Ltd. announced that it has entered into a securities purchase agreement to issue 490,907 common shares or pre-funded warrants at an issue price of $2.75 per share for gross proceeds of $1,349,994.25 and one series of warrants to purchase 687,270 common shares at an exercise price of $3.025 per share for aggregate proceeds of $1,349,994.25 on April 1, 2026. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions. The securities are being issued in a private placement under section 4(a)(2) of the securities act of 1933, as amended), and Regulation D promulgated thereunder and have not been registered under the securities act, or applicable state securities laws.
New Risk • Mar 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.57m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Mar 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (US$11.9m market cap).
お知らせ • Jan 13Newcelx Ltd. Announces Positive Results from International Collaborative StudyNewcelX Ltd. reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell-derived islets for the treatment of Type 1 Diabetes. The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin-Madison, Monash University, the Queensland University of Technology, and the Australian Foundation for Diabetes Research (AFDR), examined the use of engineered scaffolds incorporating extracellular matrix (ECM) derived from a decellularized human pancreas. The work evaluated whether ECM integration could support the function of encapsulated pluripotent stem cell-derived islets within a removable delivery system. The study results demonstrated that when ECM was incorporated into the scaffold, implanted islets exhibited functional performance comparable to encapsulated islets delivered without a scaffold. These findings suggest that biomaterial design and tissue microenvironment play a critical role in supporting islet function and may enable safer, retrievable delivery configurations for future therapeutic development. The research was supported through a Type 1 Diabetes research initiative led by the Australian Foundation for Diabetes Research, which had received donor matched funding for the published study from the National Stem Cell Foundation of Australia. Moreover, it has received dedicated funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, to further develop the underlying model based on the study results. The program integrates proprietary cell differentiation protocols with immune-protective and delivery-oriented design features, with the goal of achieving functional insulin secretion without the need for systemic immunosuppression.
お知らせ • Jan 05NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory BoardNewcelX Ltd. announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership, to its Scientific Advisory Board. Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes. In joining the NewcelX Scientific Advisory Board, Dr. Boisdron will provide high-level strategic guidance supporting the development of IsletRx, NewcelX's lead therapeutic program, a stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. Dr. Boisdron will advise on translational strategy as NewcelX advances the program toward clinical trials, including patient-adoption considerations, health-system integration, and future global commercialization frameworks.
New Risk • Dec 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.75m market cap).
お知らせ • Nov 18NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory BoardNewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board. Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and research of neurological diseases that is home to one of the largest multidisciplinary brain and spine programs in the United States and the world's largest Phase 0 clinical trials program advancing innovative neurotherapeutics Link. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS) and has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures Link. In his role on the SAB of NewcelX, Prof. Shefner will provide strategic guidance on the Company's programs in ALS, including the clinical development of AstroRx, and will support the integration of neuromuscular and neurodegenerative disease expertise into the Company's broader platform of cell therapy and neuroscience innovation.
お知らせ • Nov 07NewcelX Ltd. Appoints Tamir Ben-Hur as Scientific Advisory BoardNewcelX Ltd. announced that Professor Tamir Ben-Hur, MD, PhD, a renowned neurologist and long-time scientific advisor of Kadimastem Ltd., will join the Company's Scientific Advisory Board. Prof. Ben-Hur, a Professor of Neurology at Hadassah University Medical Center and the Hebrew University of Jerusalem, is widely recognized as a global expert in neuroimmunology and stem-cell-based regenerative medicine. The commitment of Prof. Ben-Hur to join the NewcelX Scientific Advisory Board represents a strong endorsement of the Merger and the scientific foundation on which NewcelX is being built — uniting Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.
Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). Independent External Director Liora Oren was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
